智通财经APP获悉，8月19日，归创通桥医疗科技股份有限公司(02190，以下简称"归创通桥"、"公司") 发布2025年中期业绩公告。2025年上半年，归创通桥实现营业收入4.82亿元，同比增长31.7%；净利润 突破1.21亿元，同比大幅增长76.0%，实现净利率25.1%。 报告期内，公司通桥银蛇®颅内中间导管系列、神经血管导丝、通桥麒麟™血流导向密网支架、 UltraFree®药物洗脱PTA球囊扩张导管、ZYLOX Octoplus®腔静脉滤器等产品销售规模大幅增长，市场 渗透率稳步提升。在江苏省医用耗材集采接续采购中，通桥凤™颅内动脉瘤栓塞弹簧圈顺利完成续标。 截至目前，公司已建立广泛的分销网络，覆盖超过3000家医院。公司产品自商业化以来，在临床场景的 使用数量已经突破100万个，持续为全球患者带去高质量且可负担的产品和解决方案。 在持续推进成熟产品商业化落地的同时，公司坚持差异化创新以更好满足未被满足的临床需求。今年以 来，ZYLOX Eagle®血栓抽吸系统、通桥舜封™球囊封堵止血器等产品陆续获批上市，进一步丰富产品 矩阵。下半年，大腔外周血栓抽吸导管、辅助栓塞支架、OCT引导外周血管斑块定向 ...

Core Insights - Guichuang Tongqiao Medical Technology Co., Ltd. has received approval from the Hong Kong Stock Exchange to remove the "B" designation from its stock code, marking it as the first 18A high-value consumable medical device company to achieve this milestone in the Hong Kong market [1][2] - The removal of the "B" designation signifies the company's recognition by the capital market for its sustained growth and scalable profitability, enhancing its influence in the capital market [1] - In 2024, the company achieved a revenue of 780 million yuan, representing a year-on-year growth of 48.3%, and net profit exceeded 100 million yuan, marking its first annual profit [1] Revenue and Profitability - The company announced its first cash dividend post-listing, with a total cash dividend of 32.47 million yuan (before tax), while also increasing the maximum amount for its H-share repurchase plan to 650 million HKD [1] - Since its listing in 2021, the company has accelerated its product pipeline and commercialization efforts, establishing 66 product lines, with 47 products approved for market by NMPA [2] - The company has successfully participated in multiple rounds of provincial and national centralized procurement in 2024, with key products winning bids [2] Global Expansion - The company's overseas business has shown rapid growth, achieving revenue of 22.58 million yuan in 2024, with a compound annual growth rate of 87% over the past four years [2] - Currently, 20 products have been commercialized in 24 countries and regions, including Germany, Italy, Argentina, Brazil, and the UAE [2] Leadership Vision - The Chairman and CEO, Dr. Zhao Zhong, emphasized that the successful removal of the "B" designation is a milestone for the company, which will continue to innovate and leverage its competitive advantages in product innovation and operational efficiency [2]